• 1
    Browner I, Carducci MA. Palliative chemotherapy: historical perspective, applications, and controversies. Semin Oncol 2005; 32: 14555.
  • 2
    McQuellon RP, Muss HB, Hoffman SL et al. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol 1995; 13: 85868.
  • 3
    Doyle C, Crump M, Pintilie M et al. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 2001; 19: 126674.
  • 4
    Gridelli C. Effects of vinorelbine on QOL and survival of elderly patients with advanced NSCLC. J Natl Cancer Inst 1999; 91: 6671.
  • 5
    Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899909.
  • 6
    Andreyev HJ, Norman AR, Cunningham D et al. Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF). Eur J Cancer 1995; 31A: 220914.
  • 7
    Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593600.
  • 8
    Glimelius B, Ekstrom K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 1638.
  • 9
    Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 2617.
  • 10
    Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 175664.
  • 11
    Sternberg CN, Yagoda A, Scher HI et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988; 139: 4619.
  • 12
    Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 240313.
  • 13
    Tannock IF, De Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 150212.
  • 14
    Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 151320.
  • 15
    Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 10417.
  • 16
    De Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 293847.
  • 17
    Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099106.
  • 18
    Von Der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 306877.
  • 19
    O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 281223.
  • 20
    Lofters A, Juffs HG, Pond GR et al. “PSA-itis”: knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer. J Urol 2002; 168: 251620.
  • 21
    Stirling D, Evans DGR, Pichert G et al. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international federation of gynecology and obstetrics system. J Clin Oncol 2005; 23: 558896.
  • 22
    Santillan A, Garg R, Zahurak ML et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 2005; 23: 933843.
  • 23
    Desch CE, Benson AB III, Somerfield MR et al. Colorectal cancer surveillance: 2005 update of an American society of clinical oncology practice guideline. J Clin Oncol 2005; 23: 851219.
  • 24
    Hankey BF, Feuer EJ, Clegg LX et al. Cancer surveillance series: interpreting trends in prostate cancer – part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Canc Inst 1999; 91: 101724.
  • 25
    De Vita VT Jr, Hellman S, Rosenburg SA. Cancer: Principles and Practice of Oncology, 7th edn. Lippincott Williams & Wilkins, Philadelphia, PA 2005.
  • 26
    Majumdar SR, Fletcher RH, Evans AT. How does colorectal cancer present? Symptoms, duration, and clues to location. Am J Gast 1999; 94: 303945.
    Direct Link:
  • 27
    Chute CG, Greenberg ER, Baron J et al. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer 1985; 56: 210711.
  • 28
    Stupp R, Mason WP, Van Den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 98796.
  • 29
    Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 1120.
  • 30
    Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 928.
  • 31
    Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 8591.
  • 32
    Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 251624.
  • 33
    Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22: 111825.
  • 34
    Young RC, Longo DL, Glatstein E et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988; 25: 1116.
  • 35
    Brice P, Bastion Y, Lepage E et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. J Clin Oncol 1997; 15: 111017.
  • 36
    Ardeshna KM, Smith P, Norton A et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 51622.
  • 37
    Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992; 10: 90411.
  • 38
    Ackland SP, Jones M, Tu D et al. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Br J Cancer 2005; 93: 123643.
  • 39
    O'Brien MER. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 2006; 17: 2705.
  • 40
    Ahmann DL, O'Connell MJ, Hahn RG et al. An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy. N Engl J Med 1977; 297: 35660.
  • 41
    Falkson G, Falkson HC, Glidewell O et al. Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy: a study of Cancer and Leukemia Groupe B. Cancer 1979; 43: 221522.
  • 42
    Rossof AH, Gelman R, Creech RH. Randomized evaluation of combination chemotherapy vs. observation alone following response or stabilization after oophorectomy for metastatic breast cancer in premenopausal women. Am J Clin Oncol 1982; 5: 2539.
  • 43
    Hjorth M, Hellquist L, Holmberg E et al. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I – a randomized study. Myeloma Group of Western Sweden. Eur J Haematol 1993; 50: 95102.
  • 44
    Riccardi A, Ucci G, Luoni R et al. Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 1994; 70: 120310.
  • 45
    Riccardi A, Mora O, Tinelli C et al. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 2000; 82: 125460.
  • 46
    Ahmann DL, Green SJ, Bisel HF et al. An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advances breast cancer undergoing oophorectomy: a later analysis. Am J Clin Oncol 1982; 5: 3558.
  • 47
    Falkson G, Gelman RS, Leone L et al. Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies. Cancer 1990; 66: 16219.
  • 48
    He Y, Wheatley K, Clark O et al. Early versus deferred treatment for early stage multiple myeloma. Cochrane Database Syst Rev 2003; 1: Art. no. CD004023. DOI: 10.1002/14651858.CD004023
  • 49
    Shanafelt TD, Loprinzi C, Marks R et al. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol 2004; 22: 196674.
  • 50
    De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J et al. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 2006; 17: 54352.
  • 51
    De Ruysscher D, Pijls-Johannesma M, Bentzen SM et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006; 24: 105763.
  • 52
    Ryan CJ, Small EJ. Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. J Clin Oncol 2005; 23: 822531.
  • 53
    Van Den Bent MJ, Afra D, De Witte O et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22 845 randomised trial. Lancet 2005; 366: 98590.
  • 54
    Falk SJ, Girling DJ, White RJ et al. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. BMJ 2002; 325: 465.
  • 55
    Gridelli C. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer? Lung Cancer 2002; 38 (Suppl. 2): S4550.
  • 56
    Henry B, Becouarn Y, Aussage P. Clinical benefits of stabilisation with second line chemotherapy in patients with metastatic colorectal cancer. Crit Rev Oncol Hematol 1999; 32: 14554.
  • 57
    Murad AM, Santiago FF, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 3741.
  • 58
    Mallinson CN, Rake MO, Cocking JB et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. BMJ 1980; 281: 158991.
  • 59
    Palmer KR, Kerr M, Knowles G et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81: 8825.
  • 60
    Osoba D, Tannock IF, Ernst DS et al. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999; 17: 165463.
  • 61
    Ryan CJ, Eisenberger M. Chemotherapy for hormone-refractory prostate cancer: now it's a question of “when?” J Clin Oncol 2005; 23: 82426.
  • 62
    Klotz LH. PSAdynia and other PSA–related syndromes: a new epidemic – a case history and taxonomy. Urology 1997; 50: 8312.
  • 63
    Smith MR, Kabbinavar F, Saad F et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 291825.
  • 64
    Costanza ME, Weiss RB, Henderson IC et al. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study – Cancer and Leukemia Group B 8642. J Clin Oncol 1999; 17: 1397406.
  • 65
    Holland JC, Breitbart W, Jacobsen PB. Psycho-Oncology, 1st edn. Oxford University Press, New York 1998.
  • 66
    Fitch MI, Deane K, Howell D. Living with ovarian cancer: women's perspectives on treatment and treatment decision-making. Can Oncol Nurs J 2003; 13: 820.
  • 67
    Fagerlin A, Zikmund-Fisher BJ, Ubel PA. Cure me even if it kills me: preferences for invasive cancer treatment. Med Decis Mak 2005; 25: 61419.
  • 68
    Donovan KA, Greene PG, Shuster JL et al. Treatment preferences in recurrent ovarian cancer. Gynecol Oncol 2002; 86: 20011.
  • 69
    Hirose T, Horichi N, Ohmori T et al. Patients preferences in chemotherapy for advanced non-small-cell lung cancer. Intern Med 2005; 44: 10713.
  • 70
    Balmer CE, Thomas P, Osborne RJ. Who wants second-line, palliative chemotherapy? Psychooncology 2001; 10: 41018.
  • 71
    Rose JH, O'Toole EE, Dawson NV et al. Perspectives, preferences, care practices, and outcomes among older and middle-aged patients with late-stage cancer. J Clin Oncol 2004; 22: 490717.
  • 72
    Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998; 317: 7715.
  • 73
    Yellen SB, Cella DF. Someone to live for: social well-being, parenthood status, and decision-making in oncology. J Clin Oncol 1995; 13: 125564.
  • 74
    Koedoot CG, De Haan RJ, Stiggelbout AM et al. Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice. Br J Cancer 2003; 89: 221926.
  • 75
    Koedoot CG, Oort FJ, De Haan RJ et al. The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options are: palliative chemotherapy and watchful-waiting. Eur J Cancer 2004; 40: 22535.
  • 76
    Koedoot CG, De Haes JC, Heisterkamp SH et al. Palliative chemotherapy or watchful waiting? A vignettes study among oncologists. J Clin Oncol 2002; 20: 365864.
  • 77
    Jennens RR, De Boer R, Irving L et al. Differences of opinion: a survey of knowledge and bias among clinicians regarding the role of chemotherapy in metastatic non-small cell lung cancer. Chest 2004; 126: 198593.
  • 78
    Piga A, Graziano F, Zahra G et al. Attitudes of non-oncology physicians dealing with cancer patients. A survey based on clinical scenarios in Ancona province, central Italy. Tumori 1996; 82: 4239.
  • 79
    Henry JM, Isaacs JT. Relationship between tumor size and the curability of metastatic prostatic cancer by surgery alone or in combination with adjuvant chemotherapy. J Urol 1988; 139: 111923.
  • 80
    Isaacs. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 1984; 5: 117.
  • 81
    Hiramoto RN, Ghanta VK, Soong SJ et al. Tumor burden, chemotherapy, and cell kill in osteosarcoma model. Am J Clin Oncol 1985; 8: 8996.
  • 82
    Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 1984; 44: 364353.
  • 83
    Tannock IF, Hill RP, Harrington L, Bristow RG. Basic Science of Oncology, 4th edn. McGraw-Hill Professional, New York 2005.
  • 84
    Yu JL, Rak JW, Coomber BL et al. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002; 295: 15268.
  • 85
    Durand RE. Distribution and activity of antineoplastic drugs in a tumor model. J Natl Cancer Inst 1989; 81: 14652.
  • 86
    Richards MA, Ramirez AJ, Degner LF et al. Offering choice of treatment to patients with cancers. A review based on a symposium held at the 10th annual conference of The British Psychosocial Oncology Group, December 1993. Eur J Cancer 1995; 31A: 11216.
  • 87
    Ravdin PM, Siminoff LA, Davis GJ et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19: 98091.
  • 88
    Klotz L. Active surveillance with selective delayed intervention is the way to manage “good-risk” prostate cancer. Nat Clin Pract Urol 2005; 2: 13642.
  • 89
    Smaletz O, Scher HI, Small EJ et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20: 397282.
  • 90
    Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 12327.
  • 91
    Mano A, Falcao A, Godinho I et al. CA-125 AUC as a new prognostic factor for patients with ovarian cancer. Gynecol Oncol 2005; 97: 52934.